Search
for
Sort by
Research 61–90 of 1000+
- Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
- Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
- Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
- Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases
- Adverse Dermatologic Effects of Cardiovascular Drug Therapy: Part III
- The hydroxypropyl‐β‐cyclodextrin‐minoxidil inclusion complex improves the cardiovascular and proliferative adverse effects of minoxidil in male rats: Implications in the treatment of alopecia
- Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system
- A Gender Hypothesis of sex disparities in adverse drug events
- Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
- Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Adverse events of the thyroid peroxidase inhibitor methimazole in the treatment of hyperthyroidism: a comprehensive analysis from the first quarter of 2004 to the first quarter of 2025
- Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
- Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
- Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
- Mining and analysis of adverse event signals of isotretinoin based on the real-world data of FAERS database
- Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride
- A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
- Endocrine care of transpeople part I. A review of cross-sex hormonal treatments, outcomes and adverse effects in transmen
- Association of Frailty Index with Clinical BPH Progression and Serious Adverse Events: the MTOPS Trial
- Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis
- Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
- Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
- A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
- Cytokine-Targeting Biologic Therapies for Alopecia Areata: A Comprehensive Review of Mechanism of Action, Clinical Efficacy, and Adverse Events
- Expanding the therapeutic landscape of minoxidil for androgenetic alopecia: topical, oral and sublingual formulations
- Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study
- What does the research say about androgen use and cerebrovascular events?
- 605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
- A Phase 1 Study to Investigate the Effects of Cortexolone 17α‐Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity